Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07625215 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

Study acronym: CARDIOVERT
StatusRecruiting
PhasePhase 2
SponsorBayer
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date pushed from Aug 18, 2026 to Sep 1, 2026 Study sites: 29 to 30 · Eligibility criteria expanded, about 28 words · Secondary endpoints: details revised at 2 of 4 entries Show 3 more changesShow less
    • Study sites: 29 to 30
    • Eligibility criteria expanded, about 28 words
    • Secondary endpoints: details revised at 2 of 4 entries
  2. Recruitment opened Study sites: 27 to 29 · Start date changed from estimate of Aug 31, 2026 to Aug 18, 2026v4 Show 2 more changesShow less
    • Study sites: 27 to 29
    • Start date changed from estimate of Aug 31, 2026 to Aug 18, 2026
  3. Start date: Jul 17, 2026 to Aug 31, 2026 Study sites: 28 to 27v3 Show 1 more changeShow less
    • Study sites: 28 to 27
  4. Start date: Jun 19, 2026 to Jul 17, 2026 Site details revised at 5 of 28 sitesv2 Show 1 more changeShow less
    • Site details revised at 5 of 28 sites
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Bayer
131 trials monitored
See 7 trials at risk
Atrial Fibrillation
1,133 trials monitored
See 47 trials at risk
The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called electrical cardioversion. Electrical cardioversion is a procedure that helps the heart return to a normal rhythm. In this study, each participant will get a single intravenous (IV) infusion of either BAY 3670549 or a placebo. Participants will then be observed to see whether the heart rhythm returns to a normal rhythm. If it does not, electrical cardioversion can still be performed as planned. The study will look at how many participants return from AF to a normal rhythm, without needing electrical cardioversion and how long it takes. It will also show how many participants experience medical problems after treatment and how BAY 3670549 move into, through and out of the participants' body. The total duration of the study for an individual participant may be up two months. The findings from this study may contribute to the development of a new treatment option for people with AF.
Trial Details
NCT Number NCT07625215
Lead Sponsor Bayer
Conditions Atrial Fibrillation
Enrollment 360 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov